National

Russian region in Siberia cancels injury allowance for soldiers

Dec 24, 2024

Moscow [Russia], December 24: Authorities in the Russian region of Transbaikal in Siberia have cancelled the one-off payment for soldiers who have suffered permanent injury after being wounded in the war in Ukraine.
The compensation previously amounted to between 100,000 and 500,000 roubles ($1,000 and $5,000), depending on the severity of the disability, according to the Telegram channel Sibirski Express.
The regional Ministry of Social Affairs explained that the money would instead be used to provide medical treatment and care for soldiers, and for a fuel allowance.
It was only in November that the Russian government, on the instructions of President Vladimir Putin, decided on differentiated payments for the wounded at the national level.
While this was officially justified by the fact that the seriously injured should receive more money in the future, according to the media, many groups of injured people are now receiving less compensation.
Russia has been waging a war against Ukraine for almost three years.
According to Western estimates, well over 100,000 Russian soldiers have been killed and around 500,000 wounded since the war began. (DPA)
Source: Qatar Tribune

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025